Ceftriaxone reduces L -dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model

Characterizing the differential roles of striatal 5-HT 1A auto- and hetero-receptors in the reduction of l -DOPA-induced dyskinesia

(2017) Samantha M. Meadows et al.   EXPERIMENTAL NEUROLOGY

On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats

(2016) Manolo Carta et al.   MOVEMENT DISORDERS

Monoamine transporter contributions to l -DOPA effects in hemi-parkinsonian rats

(2016) Melissa M. Conti et al.   NEUROPHARMACOLOGY

Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease

(2015) Kou Takahashi et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Conditional Deletion of the Glutamate Transporter GLT-1 Reveals That Astrocytic GLT-1 Protects against Fatal Epilepsy While Neuronal GLT-1 Contributes Significantly to Glutamate Uptake into Synaptosomes

(2015) G. T. Petr et al.   JOURNAL OF NEUROSCIENCE

Executive function deficits and glutamatergic protein alterations in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease

(2015) Lacey Pflibsen et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity

(2015) Giovanna Paolone et al.   MOVEMENT DISORDERS

New treatments for levodopa-induced motor complications

(2015) Olivier Rascol et al.   MOVEMENT DISORDERS

M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia

(2015) Weixing Shen et al.   NEURON

Ceftriaxone prevents and reverses behavioral and neuronal deficits in an MPTP-induced animal model of Parkinson's disease dementia

(2015) Chao-Yu Hsu et al.   NEUROPHARMACOLOGY

Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and l-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist

(2015) Hanna Iderberg et al.   NEUROPHARMACOLOGY

Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease: Figure 1

(2014) M. Angela Cenci   BIOCHEMICAL SOCIETY TRANSACTIONS

Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease

(2014) Manuela Pilleri et al.   Expert Opinion On Drug Safety

ser31 tyrosine hydroxylase phosphorylation parallels differences in dopamine recovery in nigrostriatal pathway following 6-OHDA lesion

(2014) Michael F. Salvatore   JOURNAL OF NEUROCHEMISTRY

Ceftriaxone Protects Astrocytes from MPP+ via Suppression of NF-κB/JNK/c-Jun Signaling

(2014) Yunlong Zhang et al.   MOLECULAR NEUROBIOLOGY

Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats

(2014) Rohit Bisht et al.   NEUROTOXICOLOGY

The effects of the β-lactam antibiotic, ceftriaxone, on forepaw stepping and l-DOPA-induced dyskinesia in a rodent model of Parkinson’s disease

(2014) John E. Kelsey et al.   PSYCHOPHARMACOLOGY

Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications

(2014) M. Angela Cenci   Frontiers in Neurology

Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease

(2013) Jeffrey H. Kordower et al.   BRAIN

Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: Effects of combined treatment and possible mechanisms of action

(2013) Hanna Iderberg et al.   EXPERIMENTAL NEUROLOGY

Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia

(2013) Christopher Kobylecki et al.   EXPERIMENTAL NEUROLOGY

Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model

(2013) Tanya Chotibut et al.   MOLECULAR NEUROBIOLOGY

Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial

(2013) F. Ory-Magne et al.   NEUROLOGY

Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis

(2013) James D. Berry et al.   PLoS One

Transient striatal GLT-1 blockade increases EAAC1 expression, glutamate reuptake, and decreases tyrosine hydroxylase phosphorylation at ser19

(2012) Michael F. Salvatore et al.   EXPERIMENTAL NEUROLOGY

Dopamine Transporter Loss in 6-OHDA Parkinson’s Model Is Unmet by Parallel Reduction in Dopamine Uptake

(2012) Tanya Chotibut et al.   PLoS One

Ceftriaxone Ameliorates Motor Deficits and Protects Dopaminergic Neurons in 6-Hydroxydopamine-Lesioned Rats

(2011) T. C. H. Leung et al.   ACS Chemical Neuroscience

Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats

(2011) Kristin B. Dupre et al.   EXPERIMENTAL NEUROLOGY

Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson’s disease

(2010) Christopher Kobylecki et al.   JOURNAL OF NEUROCHEMISTRY

Long-term antidyskinetic efficacy of amantadine in Parkinson's disease

(2010) Elisabeth Wolf et al.   MOVEMENT DISORDERS

Time-dependent changes in GLT-1 functioning in striatum of hemi-Parkinson rats

(2010) Ann Massie et al.   NEUROCHEMISTRY INTERNATIONAL

Vulnerability to glutamate toxicity of dopaminergic neurons is dependent on endogenous dopamine and MAPK activation

(2009) Yasuhiko Izumi et al.   JOURNAL OF NEUROCHEMISTRY

Effects of subthalamic nucleus lesions and stimulation upon glutamate levels in the dopamine-depleted rat striatum

(2009) Ruth H. Walker et al.   NEUROREPORT

Downregulation of glial glutamate transporters after dopamine denervation in the striatum of 6-hydroxydopamine-lesioned rats

(2008) E.K.Y. Chung et al.   JOURNAL OF COMPARATIVE NEUROLOGY

Treatment of levodopa-induced motor complications

(2008) Fabrizio Stocchi et al.   MOVEMENT DISORDERS

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism

(2008) John G. Nutt et al.   MOVEMENT DISORDERS

Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse

(2008) B.R. Miller et al.   NEUROSCIENCE

Silicon Wafer-Based Platinum Microelectrode Array Biosensor for Near Real-Time Measurement of Glutamate in Vivo

(2008) Kate Wassum et al.   SENSORS

Nigrostriatal denervation does not affect glutamate transporter mRNA expression but subsequent levodopa treatment selectively increases GLT1 mRNA and protein expression in the rat striatum

(2003) J.-C. Liévens et al.   JOURNAL OF NEUROCHEMISTRY